Serum levels of insulin-like growth factor I, II, and binding protein 3, transforming growth factor beta-1, soluble fas ligand and superoxide dismutase activity in stomach cancer cases and their controls in the JACC Study.
BACKGROUND
The prognosis of stomach cancer with advanced stage remains poor. New biomarkers of the disease that may contribute to establish the potential screening strategy would be of value for the early detection of individuals at high risk of the disease.


METHODS
We conducted a prospective, nested case-control analysis among apparently healthy men and women who were followed for up to 8 years in the Japan Collaborative Cohort (JACC) Study, to evaluate serum levels of insulin-like growth factor I, II, and binding protein 3 (IFG-I, IGF-II, and IGFBP-3), transforming growth factorbeta-1 (TGFbeta1), soluble fas (sFas) and superoxide dismutase activity (SOD) in 210 stomach cancer cases diagnosed in the JACC Study in relation to those levels in their 410 controls.


RESULTS
Among 6 serum biomarkers tested for case-control differences, only sFas level in female stomach cancer cases was significantly higher than that of controls (2.22 pg/ml vs. 2.04 pg/mL, respectively; P=0.013 by two-way analysis of covariance controlling for matching variable).


CONCLUSIONS
None of the biomarkers consistently predicted future risk of stomach cancer in both men and women in the present analysis. Serum sFas level in women, however, should be studied much more thoroughly whether it provides meaningful refinement of risk stratification, or it elucidate the mechanisms of tumorigenesis in women.
Yatsuya
Hiroshi
H
Department of Public Health/ Health Information Dynamics, Nagoya University Graduate School of Medicine, Japan. h828@med.nagoya-u.ac.jp
Toyoshima
Hideaki
H
Tamakoshi
Koji
K
Tamakoshi
Akiko
A
Kondo
Takaaki
T
Hayakawa
Norihiko
N
Sakata
Kiyomi
K
Kikuchi
Shogo
S
Hoshiyama
Yoshiharu
Y
Fujino
Yoshihisa
Y
Mizoue
Tetsuya
T
Tokui
Noritaka
N
Yoshimura
Takesumi
T
D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D053222:Fas Ligand Protein; D005260:Female; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000097:blood*; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D007564:Japan; D008297:Male; D008562:Membrane Glycoproteins / Q000097:blood*; D008875:Middle Aged; D011446:Prospective Studies; D013274:Stomach Neoplasms / Q000097:blood*; D013482:Superoxide Dismutase / Q000097:blood*; D016212:Transforming Growth Factor beta / Q000097:blood*; D053773:Transforming Growth Factor beta1
C505661:FASLG protein, human; D053222:Fas Ligand Protein; D018972:Insulin-Like Growth Factor Binding Protein 3; D008562:Membrane Glycoproteins; C508960:TGFB1 protein, human; D016212:Transforming Growth Factor beta; D053773:Transforming Growth Factor beta1; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II; D013482:Superoxide Dismutase